Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00284011
Recruitment Status : Completed
First Posted : January 31, 2006
Last Update Posted : January 6, 2012
Information provided by (Responsible Party):
Dietlind Wahner-Roedler, Mayo Clinic

Brief Summary:
The purpose of this study is to determine if the oral intake of the dietary supplement SAMe increases blood homocysteine levels in healthy human subjects.

Condition or disease Intervention/treatment Phase
Heart Disease Dietary Supplement: SAMe Other: Placebo Not Applicable

Detailed Description:
S-adenosyl-L-methionine (SAMe or AdoMet) is a commonly used nutritional supplement available in the United States since 1999. SAMe is metabolized to homocysteine, a known cardiovascular risk factor. No study has determined the effect exogenous SAMe administration has on the long-term levels of homocysteine in humans. As a nutritional supplement, SAMe is not regulated by the Food and Drug Administration, despite being used to treat clinical diseases such as depression and osteoarthritis.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of the Dietary Supplement S-Adenosyl-L-Methionine on Plasma Homocysteine Levels in Healthy Human Subjects
Study Start Date : June 2005
Actual Primary Completion Date : April 2006
Actual Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Methionine
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: SAMe
Two 400 mg pills.
Dietary Supplement: SAMe
800 mg dose daily for 4 weeks.
Other Names:
  • AdoMet
  • S-Adenosyl-L-Methionine
Placebo Comparator: Placebo
Two placebo pills (identical in appearance to SAMe).
Other: Placebo
2 placebo pills daily for 4 weeks.

Primary Outcome Measures :
  1. Homocysteine levels pre- and post- one month of SAMe administration. [ Time Frame: 1 Month ]

Secondary Outcome Measures :
  1. An interim (2 week) homocysteine level, high sensitivity C-reactive protein (hsCRP) level, lipid studies, and liver blood tests. [ Time Frame: 2 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Women and men age 18 - 65
  • Able to understand and sign a consent form

Exclusion criteria:

  • Smoking
  • Pregnant or lactating
  • Women actively trying to conceive
  • Diagnosis of panic disorder or bipolar disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00284011

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Dietland Wahner-Roedler, M.D. Mayo Clinic

Publications of Results:
Responsible Party: Dietlind Wahner-Roedler, Principal Investigator, Mayo Clinic Identifier: NCT00284011     History of Changes
Other Study ID Numbers: 677-04
First Posted: January 31, 2006    Key Record Dates
Last Update Posted: January 6, 2012
Last Verified: January 2012

Keywords provided by Dietlind Wahner-Roedler, Mayo Clinic:
Dietary Supplement

Additional relevant MeSH terms:
Heart Diseases
Cardiovascular Diseases